Header
For Healthcare Professionals
Metalyse Logo
Metalyse Banner
METALYSE® 25 MG IS NOW AVAILABLE FOR THE THROMBOLYTIC TREATMENT OF ACUTE ISCHAEMIC STROKE WITHIN 4.5 HOURS FROM LAST KNOWN WELL AND AFTER EXCLUSION OF INTRACRANIAL HAEMORRHAGE1

Because Every
Minute Matters

Single IV bolus administration

Metalyse® 25 mg is administered by a single IV bolus over 5 to 10 seconds, eliminating the need for a one-hour infusion, as required for Actilyse®1-3

Single IV bolus administration

Metalyse® is quick and easy to use and does not require an infusion pump - simplifying preparation, saving time and cost, as well as reducing dosing errors*1-5

Metalyse® 25 mg is administered 
by a single IV bolus injection over 5 to 10 seconds3-4

  • Metalyse® 25 mg comes as one single vial of powder for reconstitution, regardless of the patient

  • The dosing for Metalyse® 25 mg is simple with only 5
weight-based tiers:

Weight (kg)Volume (ml)Tenecteplase (U)Tenecteplase (mg)
< 603300015
≥ 60 to < 703.5350017.5
≥ 70 to < 804400020
≥ 80 to <904.5450022.5
≥ 905500025

Why is Metalyse® 25 mg quicker and easier to use compared to Actilyse®?

Tenecteplase is a genetically modified version of alteplase. Mutations in the protein sequence increased the specificity of Metalyse® (tenecteplase) to fibrin and made it more resistant to natural inhibitors, which increased its half-life and allowed for shorter treatment duration.6-7

Why is Metalyse® 25 mg quicker and easier to use compared to Actilyse®?

Footnotes

  • IV: intravenous; PAI-1: plasminogen activator inhibitor-1
  • *
    One of the common contributing factors that led to dosing errors associated with alteplase administration was the infusion pump being programmed incorrectly. Additionally, a single IV bolus administration avoids the interruption of treatment, further reducing dosing errors.
  • †
    Tenecteplase was administrated within 4.5 hours after onset of stroke symptoms, as a weight-tiered bolus dose, based on 0.25 mg/kg by 10 kg steps, for the maximum weight at each tier: < 60 kg, 15 mg tenecteplase; ≥ 60 to < 70 kg, 17.5 mg; ≥ 70 to < 80 kg, 20 mg; ≥ 80 to < 90 kg, 22.5 mg; and ≥ 90 kg, 25 mg.

References

  1. Metalyse® European Summary of Product Characteristics.

  2. Menon BK, et al. Lancet 2022;400:161-169.

  3. Bivard A, et al. Lancet Neurol. 2022;21:520-27.

  4. Actilyse® European Summary of Product Characteristics.

  5. Dancsecs K. A. et al. Am J Emerg Med. 2021;47:90-94.

  6. Miller, SE and Warach, SJ. Neurotherapeutics 2023;20:664–678.

  7. Zhu A, et al. Res Pract Thromb Haemost. 2022;6:e12795.

  8. Huang X, et al. Stroke. 2015;46(12):3543–6.

  9. Tanswell P, et al. Clin Pharmacokinet. 2002;41(15):1229–45.